🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› EU
Clinical trial register · European Union · CTIS

Recently authorised EU trials

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12445 total CTIS records — a stated recency window, not the full historical archive. Synced 20 Sep 2026, 03:17 UTC
2500
Shown in this register
most recently authorised
12,445
Total on CTIS
full historical archive
745
Phase III
within the shown window
Top member states
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524
Narrow the register
Phase
Phase I 558 Phase I/II 214 Phase II 726 Phase III 745 Phase IV 257
Lead sponsor
AstraZeneca AB 60 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 48 Pfizer Inc. 45 Novo Nordisk A/S 42
Member state
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524 Belgium 426 Czechia 327
All 28 states
2500 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase III
Antibiotikapenetration og vævsrespons ved infektion og rekonstruktiv kirurgi i hoved-hals regionen
2026-526995-22-00Treatment and prevention of post operative infections
Region Midtjylland
Bacterial Infections and Mycoses
Denmark
02/09/2026
Phase I
A randomized, placebo-controlled trial, to evaluate the safety, immunogenicity and the optimal dose of MOPEVAC-Las vaccine candidate against Lassa Fever, in healthy volunteers consisting of an unblinded dose escalation and a blinded treatment phase (FIRST-IN-MOP)
2025-524034-26-02Lassa fever
Institut Pasteur
Virus Diseases
France
01/09/2026
Phase I
A study to test how well different doses of BI 4060107 are tolerated by people with advanced cancer (solid tumours)
2026-525187-18-00solid tumours
Aimed Bio lnc.
Neoplasms
France
01/09/2026
Phase I
PRadR 2 - A single center, open-label, Phase I study evaluating 161Tb-PSMA therapy in adult patients with metastatic clear cell renal cell carcinoma
2026-525526-38-00Metastatic clear cell renal cell carcinoma
Centre Leon Berard
Therapeutics
France
01/09/2026
Phase III
Effect of GABAergic treatments on cortical plasticity and motor learning capacity in the subacute phase after stroke: a single-case experimental study (GABAPLAST)
2026-526884-39-00Stroke
Centre Hospitalier Universitaire De Toulouse
Nervous System Diseases
France
01/09/2026
Phase II
A phase II, open-label, randomized, multi-center study comparing the efficacy and safety of Sacituzumab govitecan versus investigator's choice in patients with cancer of unknown primary (CUP) who are relapsed after or refractory to platinum-based chemotherapy (SACICUP)
2025-523055-55-00Neoplasm
Universitaetsklinikum Heidelberg AöR
Neoplasms
Germany
01/09/2026
Phase II
Randomized, Multicenter, Vehicle-Controlled, Double-Masked Study to Evaluate the Efficacy and Safety of Intranasal Cenegermin (Recombinant Human Nerve Growth Factor [rhNGF]) in Adult Participants with Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
2025-524748-37-00Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
Dompe' Farmaceutici S.p.A.
Eye Diseases
Denmark, Italy, Germany, Hungary, Netherlands, Spain, Belgium, France, Portugal
01/09/2026
Phase III
Randomized, controlled, multi-center trial to evaluate the efficacy, tolerability, and safety of an (S)-ibuprofen gel vs. placebo in the local symptomatic and short-term treatment of pain in acute contusions of the soft tissues following blunt trauma
2025-524451-31-00acute contusions of soft tissues
Aponia Laboratories Inc.
Skin and Connective Tissue Diseases
Germany
01/09/2026
Phase II
A multicenter, prospective, randomized, placebo and non-surgical standard of care (NSSOC) controlled study, performed to evaluate the safety and efficacy of EscharEx and its placebo (gel vehicle) compared to NSSOC in participants with Venous Leg Ulcers (VLU)
2026-526070-16-00Venous Leg Ulcer (VLU)
Mediwound Ltd.
Skin and Connective Tissue Diseases
Czechia, Slovakia
01/09/2026
Phase III
A Phase III Open-Label, Randomised, Multicentre Study of Consolidation with a Single Administration of AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against BCMA and CD19, Compared with Continuous Standard Therapy in Participants with NDMM Who Are Ineligible to Receive ASCT as Initial Therapy (DURGA-5).
2025-524014-29-00Newly Diagnosed Multiple Myeloma
AstraZeneca AB
Neoplasms
Poland, Italy, Denmark, France, Sweden, Germany, Spain
01/09/2026
Phase II
A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of VQ-101 in participants with Parkinson’s disease carrying a heterozygous mutation of GBA1
2026-525848-15-00GBA1-associated Parkinson’s disease
Vanqua Bio Inc.
Nervous System Diseases
Netherlands, France, Spain, Germany
01/09/2026
Phase IV
Optimization of Dupilumab Maintenance Dosing in Eosinophilic Esophagitis: A Phase IV, Randomized, Controlled, Single-Blind, Non-Inferiority Study
2026-526348-11-01Eosinophilic Esophagitis
Amsterdam UMC Stichting
Digestive System Diseases
Netherlands
01/09/2026
Phase III
A Phase 3, Randomized, Double-blind, Placebo‑controlled Study to Assess the Efficacy and Safety of Engasertib in Subjects With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT)
2025-524490-17-00Hereditary Hemorrhagic Telangiectasia (HHT)
Vaderis Therapeutics AG
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Hungary, Netherlands, Germany, Bulgaria, France, Italy, Lithuania, Spain, Belgium
31/08/2026
Phase II
Clinical Study of Local and Systemic biological Impact of GLP1/GIP-Receptor Agonists in patients with Breast Cancer: The CLARA trial
2026-525820-76-00Hormone Receptor positive postmenopausal breast cancer
UZ Leuven
Neoplasms
Belgium
31/08/2026
Phase I/II
​​Perioperative zanidatamab combined with chemotherapy in HER2-positive locally advanced operable gastroesophageal adenocarcinoma (GEA): a Phase 1b/2a single-arm trial​
2025-523483-20-00Gastroesophageal adenocarcinoma (GEA)
UZ Leuven
Neoplasms
Belgium
31/08/2026
Phase I/II
An Open-Label, Multicenter Phase 1/2 Study to Assess the Safety, Tolerability, and Efficacy of Intracochlear Ascending Dose Injections of SENS-601 Followed by Expansion Cohort in Pediatric Population With Hearing Loss Related to Biallelic Pathogenic Variation(s) of GJB2, As Well As to Demonstrate the Performance of the Administration System, Its Safety, Its Clinical Benefit, and Its Usability.
2026-525698-38-00Hearing Loss Related to biallelic pathogenic variation (s) …
Sensorion
Otorhinolaryngologic Diseases
France
31/08/2026
Phase III
A Phase 3, Randomized, Double-Blinded Study to Evaluate the Safety and Efficacy of Salanersen (BIIB115) After Onasemnogene Abeparvovec Treatment in Infants with Genetically Diagnosed Spinal Muscular Atrophy
2025-523857-32-00Spinal Muscular Atrophy
Biogen Idec Research Limited
Nervous System Diseases
Portugal, Italy, Belgium, Croatia, Hungary, Germany, Ireland, France, Norway, Poland
31/08/2026
Phase II
A Phase II, single-arm trial on the addition of the DLL3xCD3 bispecific T-cell engager obrixtamig (BI 764532) to standard-of-care platinum-based first-line treatment of advanced large-cell neuroendocrine carcinoma of the lung (ALPINE 2)
2025-524345-28-00Male and female adult patients with locally advanced or met…
Technische Universitaet Dresden
Neoplasms
Germany
31/08/2026
Phase III
Evaluation of the Impact of a Strategy of Perioperative NSAID Suppression in Patients Undergoing Video-assisted Thoracic Surgery (VATS) on the Presence of Chronic Postoperative Pain (CPOP): a Randomised Clinical Trial (EVADRAINS)
2025-524917-96-00Thoracic surgery
Les Hopitaux Universitaires De Strasbourg
Not possible to specify
France
31/08/2026
Phase I
A research study looking at the effect of timing of meal after dosing and water volume at dosing on how the medicine zenagamtide is taken up by the body of participants with overweight or obesity
2025-521383-35-00overweight/obesity
Novo Nordisk A/S
Not possible to specify
Germany
31/08/2026
Phase III
Targeted versus standard peri-operative prophylaxis in patients colonized with carbapenemase-producing Enterobacterales undergoing liver transplantation: a stepped-wedge cluster randomization trial
2025-523453-34-00Patients colonized with CPE undergoing liver transplantatio…
Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico
Bacterial Infections and Mycoses
Italy
31/08/2026
Phase II
In-vivo fluorescence molecular bronchoscopy of durvalumab-680LT in patients with unresectable stage III NSCLC after chemoradiation - PulmoPrint
2026-526251-60-00Unresectable stage III non-small cell lung cancer
Universitair Medisch Centrum Groningen
Neoplasms
Netherlands
31/08/2026
Phase II
HOVON 168: Epcoritamab in Addition to R-Mini-CHOP Compared to R-Mini-CHOP in Elderly, Frail or Unfit Patients with Diffuse Large B-cell Lymphoma
2025-524230-25-00Diffuse large B-cell lymphoma (DLBCL)
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
Hemic and Lymphatic Diseases
Czechia, Denmark, Croatia, Spain, Sweden, Finland, Portugal, Ireland, Netherlands, Belgium, Norway
31/08/2026
Phase IV
Incidence and severity of postoperative delirium associated with Dexmedetomidine sedation during femur osteosynthesis in the elderly population
2025-523070-16-00Postoperative delirium
Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer
Nervous System Diseases
Spain
31/08/2026
Phase I
REGN9220 in Combination with Odronextamab in Adult Participants with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs)
2025-524780-20-00B-cell Non-Hodgkins Lymphoma (B-NHL)
Regeneron Pharmaceuticals Inc.
Hemic and Lymphatic Diseases
Belgium
31/08/2026
Rows per page Showing 101–125 of 2500
Previous 3 4 5 6 7 Next
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS). Derived from the EMA Clinical Trials Information System. Retrieved 20 September 2026. https://priyalifescience.com/clinical-trials-europe

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.